An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Active Ulcerative Colitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Erick H. Alayo Medical Corporation - Gastro SB Clinic · Chula Vista, CA
Florida · 2
- Allied Biomedical Research Institute, Inc · Miami, FL
- Gastro Health Research · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.